ArticleFolia microbiologica2025
Physalis peruviana and Lactobacillus lysates as modulators of lipid metabolism and oxidative stress: a natural alternative to statin therapy.
Article in Folia microbiologica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hyperlipidemia is a major modifiable risk factor for atherosclerosis and coronary heart disease. Although effective, current pharmacological interventions such as statins are often limited by adverse effects, including muscular pain, gastrointestinal disturbances, and increased risk of insulin resistance. Consequently, there is a growing interest in exploring safer, natural alternatives that can modulate lipid metabolism with minimal side effects. This study aimed to investigate the synergistic hypolipidemic and antioxidant effects of a combined intervention using bacterial lysates derived from Lactobacillus casei and Lactobacillus acidophilus alongside an extract of Physalis peruviana in a rat model of diet-induced hyperlipidemia. Thirty male Sprague-Dawley rats were randomly assigned to six experimental groups and treated for 7 weeks: (1) standard diet (normal control), (2) high-fat diet (HFD, hyperlipidemic control), (3) HFD + Physalis peruviana extract, (4) HFD + bacterial lysate mixture, (5) HFD + Physalis peruviana extract and bacterial lysate mixture, and (6) HFD + atorvastatin (reference drug). Lipid profiles, liver and kidney function markers, and hepatic antioxidant levels were assessed. Histopathological analyses of cardiac and hepatic tissues were also conducted. The combination of bacterial lysates and Physalis peruviana extract significantly reduced (p < 0.05) body weight, total cholesterol (TC), triglycerides (TG), low-density lipoprotein (LDL), and very low-density lipoprotein (VLDL) while significantly increasing (p < 0.05) high-density lipoprotein (HDL). This treatment also led to notable improvements in hepatic and renal function markers and enhanced hepatic antioxidant activity. Histological examination revealed reduced inflammation in cardiac and hepatic tissues of the combination-treated group, comparable to the effects observed with atorvastatin. The co-administration of Lactobacillus bacterial lysates and Physalis peruviana extract exhibited pronounced hypolipidemic and antioxidant effects, effectively mitigating diet-induced hyperlipidemia and associated organ dysfunction. These findings highlight the potential of this natural therapeutic approach as a functional alternative to conventional lipid-lowering agents in managing hyperlipidemia.
Indexed as
Identifiers
41131220What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.